Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.
TDP-43
TDP-43C9orf72
corticobasal degeneration (CBD)
frontotemporal lobar degeneration (FTLD)
limbic-predominant age-related encephalopathy neuropathological change (LATE-NC)
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
17
11
2021
received:
18
08
2021
accepted:
18
11
2021
pubmed:
26
11
2021
medline:
1
4
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Accumulating evidence suggests that patients with frontotemporal lobar degeneration (FTLD) can have pathologic accumulation of multiple proteins, including tau and TDP-43. This study aimed to determine the frequency and characteristics of concurrent tau pathology in FTLD with TDP-43 pathology (FTLD-TDP). The study included 146 autopsy-confirmed cases of FTLD-TDP and 55 cases of FTLD-TDP with motor neuron disease (FTLD-MND). Sections from the basal forebrain were screened for tau pathology with phosphorylated-tau immunohistochemistry. For cases with tau pathology on the screening section, additional brain sections were studied to establish a diagnosis. Genetic analysis of C9orf72, GRN and MAPT was performed on select cases. We found 72 cases (36%) with primary age-related tauopathy (PART), 85 (42%) with ageing-related tau astrogliopathy (ARTAG), 45 (22%) with argyrophilic grain disease (AGD) and 2 cases (1%) with corticobasal degeneration (CBD). Patients with ARTAG or AGD were significantly older than those without these comorbidities. One of the patients with FTLD-TDP and CBD had C9orf72 mutation and relatively mild tau pathology, consistent with incidental CBD. The coexistence of TDP-43 and tau pathologies was relatively common, particularly PART and ARTAG. Although rare, patients with FTLD can have multiple neurodegenerative proteinopathies. The absence of TDP-43-positive astrocytic plaques may suggest that CBD and FTLD-TDP were independent disease processes in the two patients with both tau and TDP-43 pathologies. It remains to be determined if mixed cases represent a unique disease process or two concurrent disease processes in an individual.
Identifiants
pubmed: 34823271
doi: 10.1111/nan.12778
pmc: PMC9300011
doi:
Substances chimiques
DNA-Binding Proteins
0
TARDBP protein, human
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12778Subventions
Organisme : NINDS NIH HHS
ID : U54 NS100693
Pays : United States
Informations de copyright
© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Références
Acta Neuropathol. 2013 Feb;125(2):303-10
pubmed: 23053136
Neuropathol Appl Neurobiol. 2021 Feb;47(1):61-72
pubmed: 32365404
J Histochem Cytochem. 2007 Jul;55(7):687-700
pubmed: 17341475
Acta Neuropathol. 2015 Jan;129(1):53-64
pubmed: 25367383
Curr Opin Neurol. 2019 Apr;32(2):279-291
pubmed: 30672825
J Neuropathol Exp Neurol. 2003 Dec;62(12):1287-301
pubmed: 14692704
Acta Neuropathol. 2013 Oct;126(4):545-54
pubmed: 23922030
J Mol Neurosci. 2011 Nov;45(3):384-9
pubmed: 21720721
Neuropathol Appl Neurobiol. 2011 Jun;37(4):358-65
pubmed: 20942898
Acta Neuropathol. 2016 Jan;131(1):87-102
pubmed: 26659578
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neuropathol Appl Neurobiol. 2021 Dec;47(7):931-941
pubmed: 33763863
Acta Neuropathol. 2016 Apr;131(4):571-85
pubmed: 26810071
Neuropathol Appl Neurobiol. 2014 Dec;40(7):844-54
pubmed: 24861427
J Neuropathol Exp Neurol. 2002 Jun;61(6):547-56
pubmed: 12071638
Acta Neuropathol. 2015 Apr;129(4):469-91
pubmed: 25549971
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
pubmed: 17084815
Nat Biomed Eng. 2020 Aug;4(8):787-800
pubmed: 32747831
Brain. 2019 Jun 1;142(6):1503-1527
pubmed: 31039256
Acta Neuropathol. 2011 Dec;122(6):673-90
pubmed: 22083254
Brain. 2019 Sep 1;142(9):e47
pubmed: 31359030
Brain. 2016 Dec;139(Pt 12):3237-3252
pubmed: 27797812
J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64
pubmed: 18520774
Brain. 2021 Aug 17;144(7):2186-2198
pubmed: 33693619
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
J Neuropathol Exp Neurol. 2020 Mar 1;79(3):296-304
pubmed: 31999351
Brain. 2012 Mar;135(Pt 3):693-708
pubmed: 22300873
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
Acta Neuropathol. 2013 Feb;125(2):289-302
pubmed: 23053135
Neuron. 2013 Feb 20;77(4):639-46
pubmed: 23415312
Acta Neuropathol. 2010 Jul;120(1):55-66
pubmed: 20512649
Neuropathol Appl Neurobiol. 2021 Dec;47(7):1050-1059
pubmed: 33969528
J Neuropathol Exp Neurol. 2004 Sep;63(9):911-8
pubmed: 15453090
J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46
pubmed: 12430710
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
Nat Rev Neurol. 2019 Oct;15(10):565-581
pubmed: 31501588
Acta Neuropathol. 2011 Jul;122(1):111-3
pubmed: 21644037
Neuropathol Appl Neurobiol. 2018 Dec;44(7):707-721
pubmed: 29660838
Commun Biol. 2021 Sep 21;4(1):1107
pubmed: 34548609
Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12778
pubmed: 34823271
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
J Neurol. 2018 Dec;265(12):2960-2971
pubmed: 30324308
Acta Neuropathol. 2018 Sep;136(3):389-404
pubmed: 29926172
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659
Mov Disord. 2017 Feb;32(2):246-255
pubmed: 28009087
Lancet Neurol. 2020 Feb;19(2):145-156
pubmed: 31810826
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879